Stay updated on Pembrolizumab+Cabozantinib in Head & Neck Squamous Cell Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab+Cabozantinib in Head & Neck Squamous Cell Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab+Cabozantinib in Head & Neck Squamous Cell Cancer Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    Added a new page revision tag: 'Revision: v3.5.4', and removed the previous tag 'Revision: v3.5.3'.
    Difference
    0.0%
    Check dated 2026-05-15T05:55:59.000Z thumbnail image
  2. Check
    12 days ago
    No Change Detected
  3. Check
    20 days ago
    No Change Detected
  4. Check
    27 days ago
    Change Detected
    Summary
    The page’s displayed revision/version label has been incremented from v3.5.2 to v3.5.3, reflecting a release/version update rather than changes to trial content.
    Difference
    0.0%
    Check dated 2026-04-24T05:51:48.000Z thumbnail image
  5. Check
    34 days ago
    Change Detected
    Summary
    Revision updated from v3.5.0 to v3.5.2.
    Difference
    0.0%
    Check dated 2026-04-17T02:09:13.000Z thumbnail image
  6. Check
    63 days ago
    Change Detected
    Summary
    Revision updated from v3.4.3 to v3.5.0.
    Difference
    0.0%
    Check dated 2026-03-19T01:15:39.000Z thumbnail image
  7. Check
    70 days ago
    Change Detected
    Summary
    Revision tag updated to v3.4.3; the v3.4.2 tag was removed.
    Difference
    0.0%
    Check dated 2026-03-11T19:57:37.000Z thumbnail image
  8. Check
    92 days ago
    Change Detected
    Summary
    Added Overall Survival (OS) as an endpoint with follow-up up to 3 years and introduced multiple immune cell biomarkers (CD56, CD19, CD14, CD8, CD4, CD3, CD45) at various treatment-cycle timepoints. Removed prior CD8+ and CD3+ cell change endpoints measured at baseline and early post-treatment.
    Difference
    8%
    Check dated 2026-02-18T07:22:37.000Z thumbnail image

Stay in the know with updates to Pembrolizumab+Cabozantinib in Head & Neck Squamous Cell Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab+Cabozantinib in Head & Neck Squamous Cell Cancer Clinical Trial page.